HER2, p95HER2, and HER3 expression and treatment outcome of lapatinib plus capecitabine in HER2-positive, trastuzumab-refractory metastatic breast

被引：0
|
作者：
Han, S.
Ro, J.
Paquet, A.
Huang, W.
Weidler, J.
Lee, K. S.
Park, I.
Oh, D.
Im, S.
Kim, T.
机构：
[1] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea
[2] Natl Canc Ctr, Goyang Si, South Korea
[3] Monogram Biosci Inc, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.1088
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1088
引用
收藏
页数：1
相关论文
共 50 条
  • [41] HER2 and p95HER2 Protein Expression Varies in Primary Versus Metastatic Serous Endometrial Carcinomas
    Newell, Jordan M.
    Hossler, Carrie
    Warrick, Joshua I.
    Roche, Michael
    Kesterson, Joshua P.
    LABORATORY INVESTIGATION, 2018, 98 : 442 - 442
  • [42] Correlation of trastuzumab treatment benefit with quantitative HER2 expression levels in HER2 positive metastatic breast cancer.
    Bachmeier, Beatrice
    Sperinde, Jeff
    Weidler, Jodi Marie
    Lie, Yolanda
    Chenna, Ahmed
    Winslow, John
    Engel, Jutta
    Schubert-Fritschle, Gabriele
    Sommerhoff, Christian
    Petropoulos, Christos J.
    Bates, Michael Patrick
    Huang, Weidong
    Nerlich, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [43] Nuclear HER3 localisation plays a role in trastuzumab resistance in HER2-positive breast cancer
    Hashimoto, K.
    Roxanis, I.
    Generali, D.
    Andreis, D.
    Strina, C.
    Cappelletti, M.
    Macaulay, V.
    Kong, A.
    CANCER RESEARCH, 2013, 73
  • [44] HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer
    Andrew R. Green
    Fabrício F. T. Barros
    Tarek M. A. Abdel-Fatah
    Paul Moseley
    Christopher C. Nolan
    Alice C. Durham
    Emad A. Rakha
    Stephen Chan
    Ian O. Ellis
    Breast Cancer Research and Treatment, 2014, 145 : 33 - 44
  • [45] LAPATINIB AND CAPECITABINE IN THE TREATMENT OF HER2-POSITIVE BREAST CANCER WITH BRAIN METASTASES
    Dubianski, R.
    Brewczynska, E.
    Lemanska, I.
    Szombara, E.
    Nowecki, Z. I.
    ANNALS OF ONCOLOGY, 2014, 25
  • [46] HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+breast cancer
    Green, Andrew R.
    Barros, Fabricio F. T.
    Abdel-Fatah, Tarek M. A.
    Moseley, Paul
    Nolan, Christopher C.
    Durham, Alice C.
    Rakha, Emad A.
    Chan, Stephen
    Ellis, Ian O.
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 145 (01) : 33 - 44
  • [47] Predictive value of quantitative HER2 and HER3 levels combined with downstream signaling markers in HER2-positive advanced breast cancer patients treated with lapatinib
    Duchnowska, R.
    Sperinde, J.
    Czartoryska-Arlukowicz, B.
    Mysliwiec, P.
    Winslow, J.
    Radecka, B.
    Petropoulos, C.
    Demlova, R.
    Orlikowska, M.
    Kowalczyk, A.
    Lang, I.
    Ziolkowska, B.
    Debska-Szmich, S.
    Merdalska, M.
    Grela-Wojewoda, A.
    Zawrocki, A.
    Biernat, W.
    Huang, W.
    Jassem, J.
    CANCER RESEARCH, 2017, 77
  • [48] TRASTUZUMAB-BASED THERAPY AFTER DISEASE PROGRESSION FOLLOWING LAPATINIB AND CAPECITABINE IN HER2-POSITIVE (HER2+) METASTATIC BREAST CANCER (MBC)
    Metro, G.
    Fabi, A.
    Foglietta, J.
    Russillo, M.
    Stocchi, L.
    Crino, L.
    Papaldo, P.
    Sperduti, I.
    Cognetti, F.
    Gori, S.
    ANNALS OF ONCOLOGY, 2010, 21 : 100 - 101
  • [49] p95HER2 and Breast Cancer
    Arribas, Joaquin
    Baselga, Jose
    Pedersen, Kim
    Parra-Palau, Josep Lluis
    CANCER RESEARCH, 2011, 71 (05) : 1515 - 1519
  • [50] Quantitative Measurements of Tumoral p95HER2 Protein Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab: Independent Validation of the p95HER2 Clinical Cutoff
    Duchnowska, Renata
    Sperinde, Jeff
    Chenna, Ahmed
    Haddad, Mojgan
    Paquet, Agnes
    Lie, Yolanda
    Weidler, Jodi M.
    Huang, Weidong
    Winslow, John
    Jankowski, Tomasz
    Czartoryska-Arlukowicz, Bogumila
    Wysocki, Piotr J.
    Foszczynska-Kloda, Malgorzata
    Radecka, Barbara
    Litwiniuk, Maria M.
    Zok, Jolanta
    Wisniewski, Michal
    Zuziak, Dorota
    Biernat, Wojciech
    Jassem, Jacek
    CLINICAL CANCER RESEARCH, 2014, 20 (10) : 2805 - 2813
12345